Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's diseaseMatthieu F. Bastide, Erwan Bézard, Manuela Mellone et al.|Progress in Neurobiology|2015Cited by 472
[Nphe<sup>1</sup>,Arg<sup>14</sup>,Lys<sup>15</sup>]Nociceptin‐NH<sub>2</sub>, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptorGirolamo Calò, D. Regoli, Anna Rizzi et al.|British Journal of Pharmacology|2002Cited by 163
Pharmacological Characterization of the Nociceptin/Orphanin FQ Receptor Antagonist SB-612111 [(–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5 H-benzocyclohepten-5-ol]: In Vitro StudiesBarbara Spagnolo, Girolamo Calò, Giacomo Carrà et al.|Journal of Pharmacology and Experimental Therapeutics|2007Cited by 97
Modulation of 5‐hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptinS. Sbrenna, Claudia L. Bianchi, Matteo Marti et al.|British Journal of Pharmacology|2000Cited by 72
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5‐hydroxytryptamine and noradrenaline release in the rat neocortexMatteo Marti, Michele Morari, Sara Stocchi et al.|British Journal of Pharmacology|2003Cited by 62